Iqvia Holdings Inc (NYSE:IQV) Receives Consensus Rating of “Buy” from Brokerages

Shares of Iqvia Holdings Inc (NYSE:IQV) have received a consensus rating of “Buy” from the twenty-three analysts that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $156.24.

A number of equities analysts have recently weighed in on IQV shares. TheStreet cut shares of ZTO Express (Cayman) from a “b+” rating to a “c” rating in a research report on Wednesday, May 1st. Leerink Swann initiated coverage on shares of Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They issued an “outperform” rating and a $21.00 price target on the stock. Mizuho set a $21.00 price objective on shares of Neon Therapeutics and gave the stock a “buy” rating in a research note on Friday, June 21st. Svb Leerink began coverage on shares of Alder Biopharmaceuticals in a research note on Tuesday, May 28th. They set an “outperform” rating on the stock. Finally, Credit Suisse Group lifted their target price on shares of Adobe from $300.00 to $325.00 and gave the stock a “positive” rating in a report on Wednesday, June 19th.

Shares of NYSE IQV traded down $0.46 during mid-day trading on Friday, reaching $156.11. The company had a trading volume of 10,329 shares, compared to its average volume of 1,502,436. The firm has a market capitalization of $30.88 billion, a PE ratio of 30.59, a PEG ratio of 1.92 and a beta of 0.87. Iqvia has a twelve month low of $104.90 and a twelve month high of $164.13. The stock has a 50 day simple moving average of $149.70. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.14 and a quick ratio of 1.14.

Iqvia (NYSE:IQV) last released its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.41 by $0.12. Iqvia had a net margin of 2.35% and a return on equity of 15.08%. The company had revenue of $2.68 billion during the quarter, compared to analysts’ expectations of $2.67 billion. During the same period in the prior year, the company earned $1.34 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. Sell-side analysts forecast that Iqvia will post 5.89 EPS for the current fiscal year.

In other Iqvia news, insider Ari Bousbib sold 96,000 shares of the business’s stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $150.00, for a total transaction of $14,400,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Kevin C. Knightly sold 46,080 shares of the business’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $138.06, for a total transaction of $6,361,804.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 238,080 shares of company stock valued at $36,121,805. 6.00% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in IQV. Securian Asset Management Inc lifted its stake in Iqvia by 0.5% during the 1st quarter. Securian Asset Management Inc now owns 16,374 shares of the medical research company’s stock valued at $2,355,000 after acquiring an additional 78 shares during the period. Conning Inc. boosted its stake in Iqvia by 3.6% in the 1st quarter. Conning Inc. now owns 2,600 shares of the medical research company’s stock worth $374,000 after purchasing an additional 90 shares during the period. Louisiana State Employees Retirement System boosted its position in shares of Iqvia by 1.2% during the 1st quarter. Louisiana State Employees Retirement System now owns 8,400 shares of the medical research company’s stock valued at $1,208,000 after acquiring an additional 100 shares during the last quarter. Hall Laurie J Trustee boosted its position in shares of Iqvia by 26.3% during the 1st quarter. Hall Laurie J Trustee now owns 480 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 100 shares during the last quarter. Finally, Montag & Caldwell LLC boosted its position in shares of Iqvia by 4.1% during the 1st quarter. Montag & Caldwell LLC now owns 2,686 shares of the medical research company’s stock valued at $386,000 after acquiring an additional 107 shares during the last quarter. Hedge funds and other institutional investors own 89.69% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: Price Target

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.